Concepedia

Lee H. Pai-Scherf

LH

6

Publications

653

Citations

6

H-Index

1999

Active since

Affiliations

National Cancer Institute(Current)

United States Food and Drug Administration

Center for Drug Evaluation and Research

Lee H. Pai-Scherf is an author at National Cancer Institute specializing in medicine, immunology, and oncology.

Top concepts

Publications per year

1999–2021

6

Publications

6

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond

Lee H. Pai-Scherf, Gideon M. Blumenthal, Hongshan Li et al. · The Oncologist · 2017 · 286 citations · Full text

Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor.

Lee H. Pai-Scherf, J Villa, Deborah A. Pearson et al. · PubMed · 1999 · 108 citations

, , +17

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With <i>RET</i> Gene Mutations or Fusions

Janice Kim, Diana Bradford, Erin Larkins et al. · Clinical Cancer Research · 2021 · 99 citations

, , +16

FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers.

Harpreet Singh, Geoffrey Kim, V. Ellen Maher et al. · Journal of Clinical Oncology · 2016 · 71 citations

, , +16

Pretreatment with Rituximab Does Not Inhibit the Human Immune Response against the Immunogenic Protein LMB-1

Raffit Hassan, Juanita Williams-Gould, Thelma M. Watson et al. · Clinical Cancer Research · 2004 · 52 citations

, , +27

Rows per page

1–5 of 6